Pure Global
NCT05820191

B-amyloid as a Marker for GBM Bioimaging

Universidad Central del Caribe·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Glioblastoma
Drug/Device/Intervention
Amyvid, Intravenous Solution
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Universidad Central del Caribe
Location
Bayamon,San Juan, Puerto Rico
Timeline & enrollment
Phase
Phase 2
Start date
Jul 01, 2023
End date
Jul 01, 2024
Enrollment
3 participants
Primary outcome

Measurement of Amyvid deposition in GBM tumor structures,Correlation of Amyvid deposition with components of high metabolic activity.,Correlation of Amyvid deposition with components of increased vascularization.

Summary

This project is aimed at improvement of glioblastoma (GBM) diagnostic strategies for
 discrimination of tumor progression and chemo- and radiotherapeutic treatment-related changes
 in brain tissue. The study will elucidate the diagnostic value of PET imaging with use of
 amyloid-β radioisotope tracer Amyvid (Florbetapir F18) for GBM. The results of the study will
 provide data for development of new approach for GBM diagnostics.

ICD-10 classifications
Malignant neoplasm of brainMalignant neoplasm: Brain, unspecifiedMesotheliomaMalignant neoplasm: Brain stemMalignant neoplasm: Overlapping lesion of brain
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05820191
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05820191 through Pure Global AI's free database. This Phase 2 trial is sponsored by Universidad Central del Caribe and is currently Not yet recruiting. The study focuses on Glioblastoma. Target enrollment is 3 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.